# Insulin medicines: Working

Source page: https://www.materialinsights.org/products/p_insulin_medicines/prod-working/

#### What it is

The product and the job it does, in a short paragraph

Insulin medicines replace or top up the hormone insulin in people with diabetes. They are sold as solutions or suspensions in glass vials, cartridges and pre-filled pens ^[7]^[14]. The functional unit is one vial or pen. Human insulin and modified insulin analogues are both counted. Insulin pumps, glucose monitors, bulk insulin as an ingredient, GLP-1 medicines and other diabetes medicines are left out.

as of 2026-11-13

#### How it works

How it does its job, step by step in plain words

Insulin is a peptide hormone ^[6]. The medicine is injected under the skin ^[5]. Some products act fast, to cover meals, and others act over many hours or, in the newest product on sale in India, a week ^[10]. Human insulin has the same amino-acid sequence as the natural hormone; analogues are modified molecules, the first rapid one being Humalog in 1996 ^[5]. The medicine is made by microbes carrying the human gene ^[3]^[6]. Vials are drawn into a syringe, while pens carry a cartridge and a dose dial. The twin technology page explains the medical use.

as of 2026-11-13

#### Key specifications

The numbers that describe it, each with unit, variant, year and source

| Spec | Value | Unit | Variant | Year | Source |
|---|---|---|---|---|---|
| Strength of the four WHO-prequalified human insulins in vials and cartridges (Novo Nordisk A/S) | 100 | IU per ml | Human | 2022 | ^[7] |
| Time the prequalified human insulins may be kept at up to 30 degrees C before opening | 4 | weeks | Human | 2022 | ^[7] |
| Pens used by a patient in a year on once-daily basal insulin (France, modelled by authors from Novo Nordisk and Putnam) | 22 | pens per year | – | 2024 | ^[14] |
| Pens used by a patient in a year on once-weekly basal insulin (France, modelled by authors from Novo Nordisk and Putnam) | 5 | pens per year | – | 2024 | ^[14] |
| Size of the larger pen of the once-weekly insulin Awiqli sold in India (1 ml and 3 ml pens, as reported) | 3 | ml (larger pen) | Analogue | 2026 | ^[10] |

as of 2026-11-13

#### Variants

The variants whose make-up or footprint differs a lot, what defines each and its share of units

| Variant | Defining spec | Year | Source |
|---|---|---|---|
| Human | Same amino-acid sequence as the natural hormone; made by microbes since the FDA approved Humulin in 1982 ^[3]^[5] | 1982 | ^[3]^[5] |
| Analogue | Modified molecule (rapid, long or once-weekly acting); the first rapid analogue, Humalog, dates from 1996, and once-weekly basal insulins are analogues too; WHO says analogues cost at least 1.5 times human insulins ^[1]^[5] | 1996 | ^[1]^[5] |

as of 2026-11-13

#### Limits

The physical limits set by science and the engineering limits of today's design, with today's value

| Limit | Kind | Limit | Today | Unit | Source |
|---|---|---|---|---|---|
| Time out of refrigeration allowed before opening, human insulin vials and cartridges (Novo Nordisk, WHO-prequalified) | Engineering | 4 | 4 | weeks at up to 30 degrees C | ^[7] |
| Time between basal insulin doses: once-weekly products against once-daily | Engineering | – | 7 | days (weekly product, India 2026; no limit stated) | ^[10] |

as of 2026-11-13

#### Science it relies on

The science principles it works by or is limited by
 Relies on

- [Hormones](https://www.materialinsights.org/science/hormones/) Insulin is a hormone: it carries a message from the blood to cells that tells them to take up sugar.
- [Microbial fermentation](https://www.materialinsights.org/science/fermentation_microbial/) Novo Nordisk uses yeast to make the recombinant insulin precursor; other makers use E. coli bacteria ^[6].

as of 2026-11-13

#### Sources

1. [New WHO report maps barriers to insulin availability and suggests actions to promote universal access](https://www.who.int/news/item/12-11-2021-new-who-report-maps-barriers-to-insulin-availability-and-suggests-actions-to-promote-universal-access) World Health Organization, 2021, news item of 12 November 2021
2. [Insulin Development and Commercialization](https://www.Acs.Org/content/dam/acsorg/education/whatischemistry/landmarks/insulin/insulin-booklet.pdf) American Chemical Society (National Historic Chemical Landmark), 2023, landmark booklet, © 2023 American Chemical Society
3. [100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future](https://pmc.ncbi.nlm.nih.gov/articles/PMC10968222) Biomedicines (MDPI), on PubMed Central, 2024
4. [Insulin: Recombinant Production, Sustainability, and Chemistry](https://oxfordglobal.com/biologics/resources/insulin-recombinant-production-sustainability-and-chemistry) Oxford Global (article by Tom Cohen on a presentation by Thomas Høeg-Jensen, Scientific Director at Novo Nordisk), 2023, page of 25 April 2023
5. [First human insulins prequalified](https://extranet.who.int/pqweb/news/first-human-insulins-prequalified) World Health Organization, Prequalification of Medical Products, 2022, news item of 28 September 2022
6. [India 2030: Who Supplies the Next 10 Million?](https://www.biospectrumindia.com/features/18/28731/india-2030-who-supplies-the-next-10-million.html) BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
7. [Environmental Impact of Switching from Daily to Weekly Basal Insulin Administration in France](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4014/145501) ISPOR Europe 2024 abstract EE212 (Bellier L, Antier C, Soggiu M, Virely N, Laporte L, Sivignon M, Kind B; affiliations Putnam, Paris, and Novo Nordisk, Paris), Value in Health 27(12) S2, 2024

## Other sections

- [Summary](https://www.materialinsights.org/products/p_insulin_medicines/index.md)
- [Bill of materials](https://www.materialinsights.org/products/p_insulin_medicines/prod-bom/index.md)
- [Use case](https://www.materialinsights.org/products/p_insulin_medicines/prod-use/index.md)
- [Supply chain](https://www.materialinsights.org/products/p_insulin_medicines/prod-supply/index.md)
- [Footprint](https://www.materialinsights.org/products/p_insulin_medicines/prod-footprint/index.md)
- [Evolution](https://www.materialinsights.org/products/p_insulin_medicines/prod-evolution/index.md)
- [Interventions](https://www.materialinsights.org/products/p_insulin_medicines/prod-interventions/index.md)
